JP2016006118A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016006118A5 JP2016006118A5 JP2015183047A JP2015183047A JP2016006118A5 JP 2016006118 A5 JP2016006118 A5 JP 2016006118A5 JP 2015183047 A JP2015183047 A JP 2015183047A JP 2015183047 A JP2015183047 A JP 2015183047A JP 2016006118 A5 JP2016006118 A5 JP 2016006118A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- tumor volume
- branched
- phenyl
- straight chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(NC(C(N(C1)C1(Cc(cc1)ccc1NS(O)(=O)=O)c1c[s]c(*)n1)=O)[Rn-])=O Chemical compound *C(NC(C(N(C1)C1(Cc(cc1)ccc1NS(O)(=O)=O)c1c[s]c(*)n1)=O)[Rn-])=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22326009P | 2009-07-06 | 2009-07-06 | |
| US61/223,260 | 2009-07-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014048238A Division JP2014139208A (ja) | 2009-07-06 | 2014-03-11 | がん細胞の転移を予防するための化合物、組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080657A Division JP6505153B2 (ja) | 2009-07-06 | 2017-04-14 | がん細胞の転移を予防するための化合物、組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016006118A JP2016006118A (ja) | 2016-01-14 |
| JP2016006118A5 true JP2016006118A5 (OSRAM) | 2016-06-02 |
Family
ID=43429466
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554058A Active JP5536113B2 (ja) | 2009-07-06 | 2010-01-12 | がん細胞の転移を予防するための化合物、組成物および方法 |
| JP2014048238A Pending JP2014139208A (ja) | 2009-07-06 | 2014-03-11 | がん細胞の転移を予防するための化合物、組成物および方法 |
| JP2015183047A Pending JP2016006118A (ja) | 2009-07-06 | 2015-09-16 | がん細胞の転移を予防するための化合物、組成物および方法 |
| JP2017080657A Active JP6505153B2 (ja) | 2009-07-06 | 2017-04-14 | がん細胞の転移を予防するための化合物、組成物および方法 |
| JP2019058234A Withdrawn JP2019089866A (ja) | 2009-07-06 | 2019-03-26 | がん細胞の転移を予防するための化合物、組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554058A Active JP5536113B2 (ja) | 2009-07-06 | 2010-01-12 | がん細胞の転移を予防するための化合物、組成物および方法 |
| JP2014048238A Pending JP2014139208A (ja) | 2009-07-06 | 2014-03-11 | がん細胞の転移を予防するための化合物、組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080657A Active JP6505153B2 (ja) | 2009-07-06 | 2017-04-14 | がん細胞の転移を予防するための化合物、組成物および方法 |
| JP2019058234A Withdrawn JP2019089866A (ja) | 2009-07-06 | 2019-03-26 | がん細胞の転移を予防するための化合物、組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8569348B2 (OSRAM) |
| EP (2) | EP2451279B1 (OSRAM) |
| JP (5) | JP5536113B2 (OSRAM) |
| KR (1) | KR101426125B1 (OSRAM) |
| CN (3) | CN105412094A (OSRAM) |
| AU (1) | AU2010271105C1 (OSRAM) |
| BR (1) | BRPI1006897A2 (OSRAM) |
| CA (1) | CA2748765C (OSRAM) |
| DK (1) | DK2451279T3 (OSRAM) |
| ES (1) | ES2726946T3 (OSRAM) |
| IL (2) | IL214048A (OSRAM) |
| MX (1) | MX2011007420A (OSRAM) |
| MY (1) | MY160399A (OSRAM) |
| NZ (1) | NZ594537A (OSRAM) |
| PL (1) | PL2451279T3 (OSRAM) |
| PT (1) | PT2451279T (OSRAM) |
| RU (1) | RU2519123C2 (OSRAM) |
| SG (2) | SG10201505672TA (OSRAM) |
| TR (1) | TR201907783T4 (OSRAM) |
| WO (1) | WO2011005330A1 (OSRAM) |
| ZA (1) | ZA201105678B (OSRAM) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2004697A2 (en) | 2006-04-07 | 2008-12-24 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| WO2011005330A1 (en) | 2009-07-06 | 2011-01-13 | Akebia Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| RS52870B (sr) | 2009-11-06 | 2013-12-31 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| BR112013008452A2 (pt) * | 2010-10-07 | 2016-06-28 | Aerpio Therapeutics Inc | composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas |
| CA2850824C (en) | 2011-10-13 | 2023-01-03 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014145068A1 (en) | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| WO2015013565A1 (en) * | 2013-07-25 | 2015-01-29 | Nemucore Medical Innovations, Inc. | Platinum derivatives for hydrophobic formulations |
| US9902767B2 (en) | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| ES2739625T3 (es) | 2014-02-19 | 2020-02-03 | Aerpio Therapeutics Inc | Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas |
| WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| CN104551003B (zh) * | 2014-12-30 | 2016-08-24 | 燕山大学 | 一种以醋酸兰瑞肽为模板制备纳米铂螺旋杆的方法 |
| CN106138019A (zh) * | 2015-03-25 | 2016-11-23 | 中国科学院大连化学物理研究所 | Gpr35受体激动剂及其应用 |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| EP3101005A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101007A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| MX387804B (es) | 2015-09-23 | 2025-03-19 | Aerpio Therapeutics Inc | Metodos para tratar presion intraocular con activadores de tie-2 |
| TW201711566A (zh) * | 2015-09-28 | 2017-04-01 | 拜耳作物科學公司 | 製備ｎ－（１，３，４－㗁二唑－２－基）芳基甲醯胺之方法 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| MX2018011705A (es) | 2016-04-01 | 2019-06-10 | Therapeuticsmd Inc | Composicion farmaceutica de hormona esteroide. |
| CN105796830A (zh) * | 2016-04-19 | 2016-07-27 | 王刚 | 一种治疗鼻旁窦支气管综合征的中药 |
| KR20190031246A (ko) | 2016-07-20 | 2019-03-25 | 에르피오 세러퓨틱스 인코포레이티드 | VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체 |
| KR102011366B1 (ko) * | 2016-11-17 | 2019-10-14 | 연세대학교 산학협력단 | 암 전이 억제제의 스크리닝 방법 |
| MA49623A (fr) | 2017-07-21 | 2021-03-17 | Antabio Sas | Composés chimiques |
| WO2019165349A1 (en) * | 2018-02-26 | 2019-08-29 | Aerpio Therapeutics, Inc. | METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPß INHIBITORS |
| KR102087044B1 (ko) * | 2018-04-30 | 2020-03-10 | 인하대학교 산학협력단 | Mmp-10 또는 이를 코딩하는 유전자의 발현을 억제하는 제제를 포함하는 암 전이 억제용 조성물 |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| CN109453195B (zh) * | 2018-11-29 | 2021-04-20 | 湖南补天药业股份有限公司 | 一种用于抑制肿瘤细胞的药物组合物 |
| CA3138682A1 (en) | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| GB2589400A (en) | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| KR102249561B1 (ko) | 2019-09-24 | 2021-05-10 | 충북대학교 산학협력단 | N-아릴-2-[(6-부틸-1,3-디메틸-2,4-디옥소-1,2,3,4-테트라하이드로피리도[2,3-d]피리미딘-5-일)설페닐]아세트아마이드를 유효성분으로 함유하는 종양의 예방 및 치료용 조성물 |
| AU2020376807A1 (en) | 2019-10-29 | 2022-05-19 | EyePoint, Inc. | Small molecule activators of Tie-2 |
| CN111184726A (zh) * | 2020-02-25 | 2020-05-22 | 沈阳药科大学 | β-内酰胺类化合物的应用 |
| CA3182748A1 (en) * | 2020-06-16 | 2021-12-23 | Mannin Research Inc. | Ve-ptp inhibitors |
| CN114456143B (zh) * | 2022-02-23 | 2023-08-15 | 北京丰帆生物医药科技有限公司 | 一种uPA的抑制剂及其制备方法和应用 |
| CN119874870B (zh) * | 2024-12-13 | 2026-01-30 | 杭州师范大学 | UFMylation修饰的YAP作为靶标在制备血管衰老治疗药物和/或检测试剂中的应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673641A (en) | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| PT574048E (pt) | 1992-03-13 | 2002-12-31 | Organon Teknika Bv | Peptidos e sequencias de acido nucleico relacionados com virus de epstein-barr |
| US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| US5688781A (en) | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
| IL122614A0 (en) | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| WO1998018914A1 (en) | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
| JPH11225351A (ja) | 1998-02-04 | 1999-08-17 | Matsushita Electric Ind Co Ltd | ページャー機能を備える無線通信装置のメッセージ消去方法および装置 |
| US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| CA2360106C (en) * | 1999-02-12 | 2012-10-30 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| PT1165115E (pt) | 1999-03-26 | 2003-10-31 | Univ California | Modulacao da permeabilidade vascular por meio dos activadores do receptor tie2 |
| EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| WO2000065088A2 (en) | 1999-04-26 | 2000-11-02 | Amersham Pharmacia Biotech Ab | Primers for identifying typing or classifying nucleic acids |
| HK1045700B (zh) | 1999-04-28 | 2007-07-27 | 德克萨斯大学董事会 | 用於通过选择性抑制vegf来治疗癌症的组合物和方法 |
| WO2000070030A1 (en) | 1999-05-19 | 2000-11-23 | Amgen Inc. | Crystal of a lymphocyte kinase-ligand complex and methods of use |
| DE60023920T2 (de) | 1999-08-27 | 2006-07-20 | Sugen, Inc., South San Francisco | Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| DE60128685T2 (de) | 2000-06-23 | 2009-03-05 | Bayer Schering Pharma Aktiengesellschaft | Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren |
| HUP0303085A2 (hu) | 2000-09-27 | 2003-12-29 | The Procter & Gamble Co. | Melanokortin receptor ligandumok és ezeket tartalmazó gyógyszerkészítmények |
| AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| WO2003084565A2 (en) | 2002-04-08 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| AU2003231098A1 (en) | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US20040167183A1 (en) | 2003-02-20 | 2004-08-26 | The Procter & Gamble Company | Phenethylamino sulfamic acids |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
| US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| CN1950342B (zh) | 2004-03-15 | 2012-09-26 | 詹森药业有限公司 | 作为阿片受体调节剂的新化合物 |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| ZA200701183B (en) | 2004-07-20 | 2008-05-28 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, an their use |
| JP4943336B2 (ja) | 2004-09-28 | 2012-05-30 | アプロジェン アイエヌシー． | キメラのコイルドコイル（二重コイル）分子を使用する方法 |
| CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| WO2006116458A2 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| KR101371773B1 (ko) | 2005-12-15 | 2014-03-07 | 아스트라제네카 아베 | 암 치료를 위한, 안지오포이에틴-2 길항자와 ｖｅｇｆ-ａ,ｋｄｒ 및/또는 ｆｌｔ1 길항자의 조합물 |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| EP2004697A2 (en) | 2006-04-07 | 2008-12-24 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| CA2693383C (en) | 2006-10-27 | 2017-03-28 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| WO2009105774A2 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| PL2385763T3 (pl) | 2009-01-12 | 2018-09-28 | Aerpio Therapeutics, Inc. | Sposoby leczenia zespołu nieszczelności naczyń |
| WO2011005330A1 (en) * | 2009-07-06 | 2011-01-13 | Akebia Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| JP5583145B2 (ja) | 2009-03-03 | 2014-09-03 | アルコン リサーチ， リミテッド | レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物 |
| KR20110130454A (ko) | 2009-03-03 | 2011-12-05 | 알콘 리서치, 리미티드 | 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| RS52870B (sr) | 2009-11-06 | 2013-12-31 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| ES2877629T3 (es) | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
| BR112013008452A2 (pt) | 2010-10-07 | 2016-06-28 | Aerpio Therapeutics Inc | composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas |
| KR20140009278A (ko) | 2010-12-02 | 2014-01-22 | 마루젠세이야쿠 가부시키가이샤 | Ｔｉｅ２ 활성화제, 혈관내피증식인자(ＶＥＧＦ) 억제제, 혈관신생 억제제, 혈관 성숙화제, 혈관 정상화제, 혈관 안정화제 및 약제학적 조성물 |
| CA2850824C (en) | 2011-10-13 | 2023-01-03 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| AU2013245630A1 (en) | 2012-04-13 | 2014-10-30 | The Johns Hopkins University | Treatment of ischemic retinopathies |
| SI2880167T1 (sl) | 2012-07-31 | 2018-12-31 | The Board Of Regents Of The University Of Texas System | Postopki in sestavki za in vivo indukcijo tvorbe celic beta trebušne slinavke |
| BR112015007778B1 (pt) | 2012-10-11 | 2023-04-25 | Ascendis Pharma Ophthalmology Division A/S | Composição farmacêutica de profármacos neutralizantes de vegf ligados ao veículo para tratamento de condições oculares |
| EP4566672A3 (en) | 2012-11-08 | 2025-08-13 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| US20150290235A1 (en) | 2012-11-23 | 2015-10-15 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| WO2014145068A1 (en) | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| DK2983695T3 (da) | 2013-04-11 | 2019-09-02 | Sunnybrook Res Inst | Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister |
| JP2016522249A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用 |
| US20160130321A1 (en) | 2013-06-20 | 2016-05-12 | Gabriela Burian | Use of a vegf antagonist in treating macular edema |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| RU2676274C2 (ru) | 2013-07-11 | 2018-12-27 | Новартис Аг | Применение антагониста vegf при лечении хориоретинальных неоваскулярных нарушений и нарушений проницаемости у педиатрических пациентов |
| EP3019527A2 (en) | 2013-07-11 | 2016-05-18 | Novartis AG | Use of a vegf antagonist in treating retinopathy of prematurity |
| US9902767B2 (en) | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| RU2727022C2 (ru) | 2013-10-01 | 2020-07-17 | Сфинготек Гмбх | Способ прогнозирования риска возникновения тяжелых нежелательных сердечных явлений |
| WO2015066426A2 (en) | 2013-11-01 | 2015-05-07 | Regeneron Pharmaceuticals, Inc. | Angiopoietin-based interventions for treating cerebral malaria |
| ES2739625T3 (es) | 2014-02-19 | 2020-02-03 | Aerpio Therapeutics Inc | Proceso para la preparación de N-bencil-3-hidroxi-4-sustituido-piridin-2-(1H)-onas |
| WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| JP2015199733A (ja) | 2014-04-04 | 2015-11-12 | 国立大学法人東北大学 | 眼圧降下剤 |
| US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| WO2016049183A1 (en) | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| MX387804B (es) | 2015-09-23 | 2025-03-19 | Aerpio Therapeutics Inc | Metodos para tratar presion intraocular con activadores de tie-2 |
-
2010
- 2010-01-12 WO PCT/US2010/020822 patent/WO2011005330A1/en not_active Ceased
- 2010-01-12 NZ NZ594537A patent/NZ594537A/en not_active IP Right Cessation
- 2010-01-12 EP EP10797461.0A patent/EP2451279B1/en active Active
- 2010-01-12 JP JP2011554058A patent/JP5536113B2/ja active Active
- 2010-01-12 PT PT10797461T patent/PT2451279T/pt unknown
- 2010-01-12 CN CN201510713404.XA patent/CN105412094A/zh active Pending
- 2010-01-12 CA CA2748765A patent/CA2748765C/en not_active Expired - Fee Related
- 2010-01-12 ES ES10797461T patent/ES2726946T3/es active Active
- 2010-01-12 SG SG10201505672TA patent/SG10201505672TA/en unknown
- 2010-01-12 KR KR1020117018742A patent/KR101426125B1/ko not_active Expired - Fee Related
- 2010-01-12 PL PL10797461T patent/PL2451279T3/pl unknown
- 2010-01-12 AU AU2010271105A patent/AU2010271105C1/en not_active Ceased
- 2010-01-12 RU RU2011133835/15A patent/RU2519123C2/ru not_active IP Right Cessation
- 2010-01-12 US US12/677,550 patent/US8569348B2/en active Active
- 2010-01-12 SG SG2011045648A patent/SG172313A1/en unknown
- 2010-01-12 DK DK10797461.0T patent/DK2451279T3/da active
- 2010-01-12 TR TR2019/07783T patent/TR201907783T4/tr unknown
- 2010-01-12 CN CN201410144271.4A patent/CN103976998A/zh active Pending
- 2010-01-12 CN CN2010800121928A patent/CN102365024A/zh active Pending
- 2010-01-12 MY MYPI2011003556A patent/MY160399A/en unknown
- 2010-01-12 MX MX2011007420A patent/MX2011007420A/es active IP Right Grant
- 2010-01-12 EP EP19159755.8A patent/EP3556367A1/en not_active Withdrawn
- 2010-01-12 BR BRPI1006897A patent/BRPI1006897A2/pt not_active Application Discontinuation
-
2011
- 2011-07-12 IL IL214048A patent/IL214048A/en not_active IP Right Cessation
- 2011-08-02 ZA ZA2011/05678A patent/ZA201105678B/en unknown
-
2014
- 2014-03-11 JP JP2014048238A patent/JP2014139208A/ja active Pending
- 2014-05-08 US US14/272,689 patent/US9174950B2/en active Active
-
2015
- 2015-09-16 JP JP2015183047A patent/JP2016006118A/ja active Pending
- 2015-09-24 US US14/864,462 patent/US9949956B2/en active Active
-
2016
- 2016-10-26 IL IL248514A patent/IL248514A0/en unknown
-
2017
- 2017-04-14 JP JP2017080657A patent/JP6505153B2/ja active Active
-
2018
- 2018-03-06 US US15/913,392 patent/US20190076405A1/en not_active Abandoned
-
2019
- 2019-03-26 JP JP2019058234A patent/JP2019089866A/ja not_active Withdrawn